Shots:

• Instituto Butantan to receive $26M upfront- $75M milestones and royalties on sales from Merck. Merck to get clinical data and learnings (utilized for its TV003- dengue vaccine) from Instituto’s development programs to develop vaccines for dengue
• The focus of the agreement is to develop live attenuated tetravalent vaccines (LATV) against the dengue virus for patients suffering in Brazil
• TV003 is a LATV P-III candidate- assessing 17-000 healthy people aged 2 to 59 years in 15 cities- indicated to treat dengue infection

Ref: Merck | Image: Merck